Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients

Gastroenterology

Volumn 127, Issue 5, 2004, Pages 1347-1355

  Hinrichsen, Holger ^a   Benhamou, Yves ^b   Wedemeyer, Heiner ^c   Reiser, Markus ^d   Sentjens, Roel E ^e   Calleja, José L ^f   Forns, Xavier ^g   Erhardt, Andreas ^h   Crönlein, Jens ⁱ   Chaves, Ricardo L ⁱ   Yong, Chan Loi ^j   Nehmiz, Gerhard ⁱ   Steinmann, Gerhard G ⁱ  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d ST JOSEF HOSPITAL   (Germany)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^h UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^j BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CILUPREVIR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEADACHE; HEMATURIA; HEPATITIS C; HUMAN; HYPERTENSION; HYPOTENSION; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; PHLEBITIS; PRIORITY JOURNAL; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYNCOPE; XEROSTOMIA;

EID: 7644232426     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.08.002     Document Type: Article

References (33)

1. L.B. Seeff Natural history of chronic hepatitis C Hepatology 36 Suppl 1 2002 S35 S46
2. W.R. Kim The burden of hepatitis C in the United States Hepatology 36 Suppl 1 2002 S30 S34
3. M.J. Alter, D. Kruszon-Moran, O.V. Nainan, G.M. McQuillan, F. Gao, L.A. Moyer, R.A. Kaslow, H.S. Margolis The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556 562
4. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the viral hepatitis prevention board J Viral Hepat 6 Suppl 1999 S35 S47
5. R. Adam, V. Cailliez, P. Majno, V. Karam, P. McMaster, R.Y. Caine, J. O'Grady, R. Pichlmayr, P. Neuhaus, J.B. Otte, K. Hoeckerstedt, H. Bismuth Normalised intrinsic mortality risk in liver transplantation European Liver Transplant Registry Study Lancet 356 2000 621 627
6. G. Fattovich, M.L. Ribero, M. Pantalena, G. Diodati, P. Almasio, F. Nevens, F. Tremolada, F. Degos, J. Rai, A. Solinas, D. Mura, A. Tocco, I. Zagni, F. Fabris, L. Lomonaco, F. Noventa, G. Realdi, S.W. Schalm, A. Tagger Hepatitis C virus genotypes distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe J Viral Hepat 8 2001 206 216
7. H. Hinrichsen, G. Leimenstoll, G. Stegen, H. Schrader, U.R. Foelsch, W.E. Schmidt Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients a multicentre study in 2796 patients Gut 51 2002 429 433
8. J.G. McHutchison Hepatitis C advances in antiviral therapy what is accepted treatment now? J Gastroenterol Hepatol 17 2002 431 441
9. V. Carreno Present treatment expectations and risks of chronic hepatitis C Clin Microbiol Infect 8 2002 74 79
10. G. Chander, M.S. Sulkowski, M.W. Jenckes, M.S. Torbenson, H.F. Herlong, E.B. Bass, K.A. Gebo Treatment of chronic hepatitis C a systematic review Hepatology 36 Suppl 1 2002 S135 S144
11. A.M. Di Bisceglie, J.H. Hoofnagle Optimal therapy of hepatitis C Hepatology 36 Suppl 1 2002 S121 S127
12. S.W. Schalm, O. Weiland, B.E. Hansen, M. Milella, M.Y. Lai, A. Hollander, P.P. Michielsen, A. Bellobuono, L. Chemello, G. Pastore, D.S. Chen, J.T. Brouwer Eurohep Study Group for Viral Hepatitis Interferon-ribavirin for chronic hepatitis C with and without cirrhosis analysis of individual patient data of six controlled trials Gastroenterology 117 1999 408 413
13. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar, Z.D. Goodman, K. Koury, M. Ling, J.K. Albrecht Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial Lancet 358 2001 958 965
14. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Goncales, D. Haeussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, J. Yu Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
15. K.J. Cummings, S.M. Lee, E.S. West, J. Cid-Ruzafa, S.G. Fein, Y. Aoki, M.S. Sulkowski, S.N. Goodman Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon a meta-analysis of randomized trials JAMA 285 2001 193 199
16. P. Marcellin, T. Asselah, N. Boyer Fibrosis and disease progression in hepatitis C Hepatology 36 Suppl 1 2002 S47 S56
17. M.G. Ghany, D.E. Kleiner, H. Alter, E. Doo, F. Khokar, K. Promrat, D. Herion, Y. Park, T.J. Liang, J.H. Hoofnagle Progression of fibrosis in chronic hepatitis C Gastroenterology 124 2003 97 104
18. T. Poynard, P. Mathurin, C.L. Lai, D. Guyader, R. Poupon, M.H. Tainturier, R.P. Myers, M. Muntenau, V. Ratziu, M. Manns, A. Vogel, F. Capron, A. Chedid, P. Bedossa Panfibrosis group A comparison of fibrosis progression in chronic liver diseases J Hepatol 38 2003 257 265
19. V. Lohmann, F. Körner, J. Koch, U. Herian, L. Theilmann, R. Bartenschlager Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 285 1999 110 113
20. R. Bartenschlager, L. Ahlborn-Laake, J. Mous, H. Jacobsen Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions J Virol 67 1993 3835 3844
21. A. Grakoui, C. Wychowski, C. Lin, S.M. Feinstone, C.M. Rice Expression and identification of hepatitis C virus polyprotein cleavage products J Virol 67 1993 1385 1395
22. J.L. Kim, K.A. Morgenstern, C. Lin, T. Fox, M.D. Dwyer, J.A. Landro, S.P. Chambers, W. Markland, C.A. Lepre, E.T. O'Malley, S.L. Harbeson, C.M. Rice, M.A. Murcko, P.R. Caron, J.Al. Tomson Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide Cell 87 1996 343 355
23. R.A. Love, H.E. Parge, J.A. Wickersham, Z. Hostomsky, N. Habuka, E.W. Moomaw, T. Adachi, Z. Hostomska The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site Cell 87 1996 331 342
24. D. Lamarre, P.C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Boes, D.R. Cameron, M. Cartier, M.G. Cordingley, A.M. Faucher, N. Goudreau, S.H. Kawai, G. Kukolj, L. Lagace, S.R. LaPlant, H. Narjes, M.A. Poupart, J. Rancourt, R.E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y.S. Tzantrizos, S.M. Weldon, C.L. Yong, M. Llinas-Brunet An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 426 2003 186 189
25. H. Narjes, C. Yong, H. Stähle, G. Steinmann Tolerability and pharmacokinetics of BILN 2061, a novel oral HCV serine protease inhibitor, after oral single doses of 5 to 2400 mg in healthy male subjects (abstract) Hepatology 36 2002 363A
26. C. Sarrazin, G. Teuber, R. Kokka, H. Rabenau, S. Zeuzem Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays Hepatology 32 2000 818 823
27. J.M. Pawlotsky Use and interpretation of virological tests for hepatitis C Hepatology 36 Suppl 1 2002 S65 S73
28. J.G. Skellam A probability distribution derived from the binomial distribution by regarding the probability of success as variable between the sets of trials J R Stat Soc B 10 1948 257 261
29. M. Reiser, H. Hinrichsen, Y. Benhamou, R. Sentjens, H. Wedemeyer, L. Calleja, X. Forns, J. Croenlein, C. Yong, G. Nehmiz, G. Steinmann Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1 (abstract) Hepatology 37 2003 136
30. D. Thibeault, C. Bousquet, R. Gingras, L. Lagace, R. Maurice, P.W. White, D. Lamarre Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor 2061 J Virol 78 2004 7352 7359
31. C. Lin, K. Lin, Y.P. Luong, B.G. Rao, Y.Y. Wei, D.L. Brennan, J.R. Fulghum, H.M. Hsiao, S. Ma, J.P. Maxwell, K.M. Cottrell, R.B. Perni, C.A. Gates, A.D. Kwong In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 structural analysis indicates different resistance mechanisms J Biol Chem 279 2004 17508 17514
32. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden, A.S. Perelson Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107
33. S. Zeuzem, J.M. Schmidt, J.H. Lee, M. von Wagner, G. Teuber, W.K. Roth Hepatitis C virus dynamics in vivo effect of ribavirin and interferon alfa on viral turnover Hepatology 28 1998 245 252